Kalofonos Isabel

Chief Commercial OfficerCrinetics Pharmaceuticals, Inc. (CRNX) · full profile →Form 4 · filed Sep 1, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
2 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 1, 2026Disposed to issuer(D)2K$85.00$142K34K
Sep 1, 2026Disposed to issuer(D)34K$85.00$2.9M0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Sep 1, 2026Disposed to issuer(D)98K$44.41$4.3M0
Sep 1, 2026Disposed to issuer(D)55K$41.21$2.3M0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-26-059885) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Build on these Form 4 transactions

The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.